FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014600930> ?p ?o ?g. }

• W3014600930 endingPage "861" @default.
• W3014600930 startingPage "854" @default.
• W3014600930 abstract "European Society of Cardiology/European Atherosclerosis Society 2019 guidelines recommend more aggressive lipid targets in high- and very high-risk patients and the addition of adjuvant treatments to statins in uncontrolled patients. We aimed to assess (a) achievement of prior and new European Society of Cardiology/European Atherosclerosis Society lipid targets and (b) lipid-lowering therapy prescribing in a nationwide cohort of very high-risk patients.We conducted a retrospective observational population study using linked health data in patients undergoing percutaneous coronary intervention (2012-2017). Follow-up was for one-year post-discharge.Altogether, 10,071 patients had a documented LDL-C level, of whom 48% had low-density lipoprotein cholesterol (LDL-C)<1.8 mmol/l (2016 target) and (23%) <1.4 mmol/l (2019 target). Five thousand three hundred and forty patients had non-high-density lipoprotein cholesterol (non-HDL-C) documented with 57% <2.6 mmol/l (2016) and 37% <2.2 mmol/l (2019). In patients with recurrent vascular events, fewer than 6% of the patients achieved the 2019 LDL-C target of <1.0 mmol/l. A total of 10,592 patients had triglyceride (TG) levels documented, of whom 14% were ≥2.3 mmol/l and 41% ≥1.5 mmol/l (2019). High-intensity statins were prescribed in 56.4% of the cohort, only 3% were prescribed ezetimibe, fibrates or prescription-grade N-3 fatty acids. Prescribing of these agents was lower amongst patients above target LDL-C, non-HDL-C and triglyceride levels. Females were more likely to have LDL-C, non-HDL-C and triglyceride levels above target.There was a low rate of achievement of the new European Society of Cardiology/European Atherosclerosis Society lipid targets in this large post-percutaneous coronary intervention population and relatively low rates of intensive lipid-lowering therapy prescribing in those with uncontrolled lipids. There is considerable potential to optimise lipid-lowering therapy further through statin intensification and appropriate use of novel lipid-lowering therapy, especially in women." @default.
• W3014600930 created "2020-04-10" @default.
• W3014600930 creator A5001317469 @default.
• W3014600930 creator A5004722008 @default.
• W3014600930 creator A5005214923 @default.
• W3014600930 creator A5008354191 @default.
• W3014600930 creator A5010412005 @default.
• W3014600930 creator A5017489363 @default.
• W3014600930 creator A5031145561 @default.
• W3014600930 creator A5033011934 @default.
• W3014600930 creator A5055503133 @default.
• W3014600930 creator A5064224761 @default.
• W3014600930 date "2020-04-09" @default.
• W3014600930 modified "2023-10-01" @default.
• W3014600930 title "Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: A population-level observational cohort study" @default.
• W3014600930 cites W1998569580 @default.
• W3014600930 cites W2007976725 @default.
• W3014600930 cites W2039910385 @default.
• W3014600930 cites W2060363472 @default.
• W3014600930 cites W2085828681 @default.
• W3014600930 cites W2103873642 @default.
• W3014600930 cites W2108510859 @default.
• W3014600930 cites W2111099202 @default.
• W3014600930 cites W2587805019 @default.
• W3014600930 cites W2751423033 @default.
• W3014600930 cites W2765280011 @default.
• W3014600930 cites W2897377941 @default.
• W3014600930 cites W2903390043 @default.
• W3014600930 cites W2982549493 @default.
• W3014600930 cites W2987868385 @default.
• W3014600930 doi "https://doi.org/10.1177/2047487320914115" @default.
• W3014600930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34298561" @default.
• W3014600930 hasPublicationYear "2020" @default.
• W3014600930 type Work @default.
• W3014600930 sameAs 3014600930 @default.
• W3014600930 citedByCount "12" @default.
• W3014600930 countsByYear W30146009302020 @default.
• W3014600930 countsByYear W30146009302021 @default.
• W3014600930 countsByYear W30146009302022 @default.
• W3014600930 countsByYear W30146009302023 @default.
• W3014600930 crossrefType "journal-article" @default.
• W3014600930 hasAuthorship W3014600930A5001317469 @default.
• W3014600930 hasAuthorship W3014600930A5004722008 @default.
• W3014600930 hasAuthorship W3014600930A5005214923 @default.
• W3014600930 hasAuthorship W3014600930A5008354191 @default.
• W3014600930 hasAuthorship W3014600930A5010412005 @default.
• W3014600930 hasAuthorship W3014600930A5017489363 @default.
• W3014600930 hasAuthorship W3014600930A5031145561 @default.
• W3014600930 hasAuthorship W3014600930A5033011934 @default.
• W3014600930 hasAuthorship W3014600930A5055503133 @default.
• W3014600930 hasAuthorship W3014600930A5064224761 @default.
• W3014600930 hasBestOaLocation W30146009301 @default.
• W3014600930 hasConcept C126322002 @default.
• W3014600930 hasConcept C142724271 @default.
• W3014600930 hasConcept C201903717 @default.
• W3014600930 hasConcept C23131810 @default.
• W3014600930 hasConcept C2778163477 @default.
• W3014600930 hasConcept C2778657065 @default.
• W3014600930 hasConcept C2778913445 @default.
• W3014600930 hasConcept C2780182762 @default.
• W3014600930 hasConcept C2780400711 @default.
• W3014600930 hasConcept C2908647359 @default.
• W3014600930 hasConcept C500558357 @default.
• W3014600930 hasConcept C71924100 @default.
• W3014600930 hasConcept C72563966 @default.
• W3014600930 hasConcept C99454951 @default.
• W3014600930 hasConceptScore W3014600930C126322002 @default.
• W3014600930 hasConceptScore W3014600930C142724271 @default.
• W3014600930 hasConceptScore W3014600930C201903717 @default.
• W3014600930 hasConceptScore W3014600930C23131810 @default.
• W3014600930 hasConceptScore W3014600930C2778163477 @default.
• W3014600930 hasConceptScore W3014600930C2778657065 @default.
• W3014600930 hasConceptScore W3014600930C2778913445 @default.
• W3014600930 hasConceptScore W3014600930C2780182762 @default.
• W3014600930 hasConceptScore W3014600930C2780400711 @default.
• W3014600930 hasConceptScore W3014600930C2908647359 @default.
• W3014600930 hasConceptScore W3014600930C500558357 @default.
• W3014600930 hasConceptScore W3014600930C71924100 @default.
• W3014600930 hasConceptScore W3014600930C72563966 @default.
• W3014600930 hasConceptScore W3014600930C99454951 @default.
• W3014600930 hasFunder F4320315752 @default.
• W3014600930 hasIssue "8" @default.
• W3014600930 hasLocation W30146009301 @default.
• W3014600930 hasLocation W30146009302 @default.
• W3014600930 hasLocation W30146009303 @default.
• W3014600930 hasOpenAccess W3014600930 @default.
• W3014600930 hasPrimaryLocation W30146009301 @default.
• W3014600930 hasRelatedWork W2031596683 @default.
• W3014600930 hasRelatedWork W2069304371 @default.
• W3014600930 hasRelatedWork W2072909849 @default.
• W3014600930 hasRelatedWork W2099802986 @default.
• W3014600930 hasRelatedWork W2313325242 @default.
• W3014600930 hasRelatedWork W2316407790 @default.
• W3014600930 hasRelatedWork W3099665691 @default.
• W3014600930 hasRelatedWork W3120510923 @default.
• W3014600930 hasRelatedWork W4280552787 @default.
• W3014600930 hasRelatedWork W45151993 @default.
• W3014600930 hasVolume "28" @default.

• next